Master Health Promotion & Illness Prevention
for MCCQE Part 1

What the MCCQE Part 1 Tests in Health Promotion & Illness Prevention

This exam tests the application of evidence-based preventive medicine in Canadian and international contexts. Candidates must demonstrate knowledge of screening guidelines (e.g., CTFPHC, USPSTF), immunization schedules (e.g., NACI), and risk stratification for chronic diseases. Questions present clinical scenarios requiring decisions on screening tests (e.g., mammography, colonoscopy, DXA), counselling for lifestyle modification (e.g., smoking cessation, alcohol reduction), and chemoprophylaxis (e.g., aspirin for primary prevention, statins for dyslipidemia). Emphasis is on age- and risk-appropriate interventions, including cancer screening intervals, hypertension thresholds, and osteoporosis screening criteria. Candidates must also integrate preventive measures for infectious diseases (e.g., hepatitis B vaccination in diabetics, HPV vaccine in adolescents) and recognize when to initiate pharmacotherapy (e.g., metformin for prediabetes, bisphosphonates for osteoporosis). The exam expects familiarity with GRADE-based recommendations and shared decision-making.

High-Yield Concepts

• Cervical Cancer Screening (CTFPHC 2023): Screen women aged 25-69 with HPV testing every 5 years (primary test) or cytology every 3 years if HPV unavailable. Discontinue screening after age 69 if prior adequate negative screens. Do not screen women <25 or after total hysterectomy for benign disease.
• Colorectal Cancer Screening (CTFPHC 2016): Screen average-risk adults aged 50-74 with FOBT every 2 years or flexible sigmoidoscopy every 10 years. Colonoscopy is not first-line for average risk. Discontinue at age 75 or if life expectancy <10 years.
• Breast Cancer Screening (CTFPHC 2018): Screen women aged 50-74 with mammography every 2-3 years. Shared decision-making for women aged 40-49. No recommendation for clinical breast exam alone. High-risk women (e.g., BRCA carriers) require earlier and more frequent screening.
• Hypertension Screening and Diagnosis: Screen all adults ≥18 every 1-2 years if normotensive. Diagnose hypertension if office BP ≥140/90 on at least 2 visits, or ambulatory BP monitoring daytime average ≥135/85. Target BP <130/80 for high-risk patients (diabetes, CKD, CVD).
• Osteoporosis Screening (Osteoporosis Canada 2023): Screen with DXA (central) in women ≥65 and men ≥70, or earlier in those with risk factors (e.g., prior fragility fracture, glucocorticoid use, parental hip fracture). Treat if T-score ≤ -2.5 or if T-score between -1.0 and -2.5 with FRAX 10-year major fracture risk ≥20% or hip fracture risk ≥3%.
• Statins for Primary Prevention (CCS 2021): Calculate Framingham Risk Score (FRS) or pooled cohort equations. For patients aged 40-75 with LDL-C ≥1.8 mmol/L and FRS ≥10%, offer moderate- to high-intensity statin (e.g., atorvastatin 20-40 mg). For FRS 5-9%, consider after shared decision-making.
• Immunization Schedules (NACI 2024): Routine: DTaP-IPV-Hib at 2,4,6,18 months; MMR at 12 and 18 months; varicella at 12 months; HPV vaccine for ages 9-14 (2 doses, 6 months apart); influenza annually for all ≥6 months; COVID-19 boosters per local recommendations. Pneumococcal vaccines: PCV20 or PCV15 followed by PPSV23 for adults ≥65 or high-risk.
• Smoking Cessation (CAN-ADAPTT 2021): Use the 5As (Ask, Advise, Assess, Assist, Arrange). First-line pharmacotherapy: nicotine replacement therapy (patch, gum, lozenge), varenicline (Champix), or bupropion (Zyban). Combination therapy (patch + short-acting NRT) is more effective. Provide behavioural counselling.

Common Traps in Health Promotion & Illness Prevention Questions

• Assuming screening is always beneficial—forget that overdiagnosis and false positives (e.g., PSA in men >70) are harms.
• Mixing up CTFPHC and USPSTF guidelines (e.g., CTFPHC recommends against mammography at age 40-49 without shared decision-making, while USPSTF recommends biennial screening starting at 40).
• Using FOBT for colorectal cancer screening in patients with a family history of CRC—colonoscopy is indicated for high-risk individuals.
• Giving statins to all patients with elevated LDL-C without calculating FRS—statins are not indicated for primary prevention if FRS <5%.
• Recommending DXA screening for all postmenopausal women regardless of age or risk factors—only those ≥65 or with specific risk factors should be screened.
• Forgetting to adjust screening intervals for high-risk groups (e.g., earlier and more frequent mammography in BRCA carriers, or colonoscopy every 5 years in those with personal history of adenomas).

How to Revise Health Promotion & Illness Prevention for the MCCQE Part 1

Prioritise memorising CTFPHC screening cut-offs and intervals, as these are frequently tested with age-based scenarios. Focus on cancer screening (breast, cervical, colorectal) and cardiovascular risk stratification (FRS, LDL targets). Questions often present a patient with a specific age, sex, and risk factor profile—practise applying the correct screening test and frequency. Also, review NACI schedules for catch-up immunisations (e.g., HPV in older adolescents, pneumococcal in immunocompromised). Be prepared for 'best next step' questions that test shared decision-making or when to initiate pharmacotherapy (e.g., metformin for prediabetes if BMI ≥35 or age <60). Avoid over-reliance on absolute values; understand the rationale behind each recommendation.

Practise it: MedLumen has 50 Health Promotion & Illness Prevention questions for the MCCQE Part 1, each with a full explanation and references.